Is Leptin a Mediator of Adverse Prognostic Effects of Obesity in Breast Cancer?
Open accessThe DOI matches its Crossref record.
Abstract
Purpose: Leptin, an adipocyte-derived cytokine that is elevated in obesity, has been associated with carcinogenesis, tumor migration and invasion, enhancement of angiogenesis, and increased aromatase activity. It has been suggested that leptin may mediate adverse prognostic effects of obesity in breast cancer. Patients and Methods: Four hundred seventy-one women with surgically resected T1-3, N0-1, M0 breast cancer were studied. Leptin was assayed in stored fasting blood specimens obtained before adjuvant therapy. Women were followed prospectively for distant disease-free survival (DDFS) and overall survival (OS). Results: Patients ranged from 26 to 74 years of age, and staging was as follows: T1 = 262, T2 = 151, T3 = 23, TX = 35, N0 = 323, and N1 = 148. Estrogen receptor was positive in 286 patients, and progesterone receptor was positive in 259 patients. One hundred forty-five patients received adjuvant chemotherapy, 146 received adjuvant tamoxifen, 46 received both, and 134 received neither. Mean leptin was 15.2 ± 10.1 ng/mL. Univariately, leptin was associated with OS (overall P = .049; P = .014 postmenopausal). Leptin was not associated with DDFS overall or in any menopausal subgroup (P ≥ .19). In multivariate Cox modeling, leptin was not significantly associated with DDFS or OS (P = .11 and 0.075, respectively). Adjustment for insulin or body mass index further reduced the association of leptin with outcome. Conclusion: Although leptin is strongly correlated with obesity and insulin, we could not show that it is independently associated with prognosis in early-stage breast cancer. Because we cannot rule out modest prognostic effects, we recommend additional research to explore this potential association, particularly in postmenopausal women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Chan, D. S. M., Vieira, A. R., Aune, D., Bandera, E. V., Greenwood, D. C., McTiernan, A., Navarro Rosenblatt, D., Thune, I., Vieira, R., & Norat, T. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu042 · Cited by 1,165
“possible interaction between leptin and insulin[12], and obesityrelated markers of inflammation[13] have also been linked to breast cancer outcomes.”
BackgroundVigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0087 · Cited by 1,009
Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression
Vona-Davis, L., & Rose, D. P. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-06-0068 · Cited by 496
“Later, Goodwin et al. (2005) evaluated plasma leptin levels as a prognostic indicator in breast cancer patients, but although they did observe an association between relatively high concentrations and both higher tumor stage and grade, and negative steroid hormone receptor status, recognized…”
BackgroundAdipocyte biology in breast cancer: From silent bystander to active facilitator
Choi, J., Cha, Y. J., & Koo, J. S. (2018) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.11.002 · Cited by 255
Self-citationZimmerlin, L., Donnenberg, A. D., Rubin, J. P., Basse, P., Landreneau, R. J., & Donnenberg, V. S. (2011) · Tissue Engineering Part A · doi:10.1089/ten.tea.2010.0248 · Cited by 225
Goodwin, P. J., Segal, R. J., Vallis, M., Ligibel, J. A., Pond, G. R., Robidoux, A., Blackburn, G. L., Findlay, B., Gralow, J. R., Mukherjee, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1517 · Cited by 197
Self-citation
Metadata
- Authors
- Goodwin, P. J., Ennis, M., Fantus, I. G., Pritchard, K. I., Trudeau, M. E., Koo, J., & Hood, N.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-09-01
- Volume
- 23
- Issue
- 25
- Pages
- 6037-6042
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2155090470
- Cited by
- 86
- References
- 0
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.